Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib + Pembrolizumab in Nonsquamous NSCLC (LEAP-006 China Extension)
NCT04716933Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2019
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lenvatinib in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Merck & Co.. Started Nov 2019; status: completed.
02
Drugs
lenvatinib
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT04716933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04716933.